{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for angiotensin root_Display\ Name in Display Name (approximate match)
Status:
Investigational
Source:
NCT04313166: Phase 2 Interventional Completed Amyotrophic Lateral Sclerosis
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT04602247: Not Applicable Interventional Completed Iron Deficiency
(2020)
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Status:
Investigational
Source:
NCT03951337: Phase 2 Interventional Recruiting Rectal Cancer
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
ATSM CU-64 is an agent for imaging hypoxia in tissues. The agent was developed to be used in PET diagnostic imaging of cancer and showed positive results in phase II of clinical trials in patients with cervical cancer.
Status:
Other
Class (Stereo):
CHEMICAL (ABSOLUTE)
